- Home
- BKKT vs EDIT Comparison
BKKT vs EDIT Comparison
Compare BKKT & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BKKT | EDIT |
|---|---|---|
| Founded | 2018 | 2013 |
| Country | United States | United States |
| Employees | 559 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 246.3M | 206.0M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | BKKT | EDIT |
|---|---|---|
| Price | $9.29 | $2.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $13.00 | $4.92 |
| AVG Volume (30 Days) | 1.2M | ★ 1.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $31,937,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.04 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 132.64 |
| 52 Week Low | $6.81 | $0.91 |
| 52 Week High | $49.79 | $4.54 |
Technical Indicators
Market Signals| Indicator | BKKT | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 38.16 | 67.16 |
| Support Level | $8.90 | $2.42 |
| Resistance Level | $10.82 | $2.76 |
| Average True Range (ATR) | 0.78 | 0.19 |
| MACD | 0.06 | 0.08 |
| Stochastic Oscillator | 14.23 | 87.56 |
Price Performance
Historical ComparisonAbout BKKT Bakkt Holdings Inc.
Bakkt Inc is focused on building the backbone of next-generation financial infrastructure. The company provides financial technology solutions that support institutional participation in digital assets. Its offerings include infrastructure related to bitcoin, tokenization, stablecoin payments, and AI-enabled financial services. The company specializes in providing solutions designed to meet institutional requirements for security, scale, and regulatory compliance.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.